Down 99%, biotech firm 180 Life Sciences pivots to crypto with ETH bet
Main Idea
Nasdaq-listed biotech firm 180 Life Sciences is pivoting to cryptocurrency, planning to invest heavily in Ether and rebrand as ETHZilla Corporation, amid significant financial struggles and a sharp decline in stock value.
Key Points
1. 180 Life Sciences Corp, a Nasdaq-listed biotech firm, announced a $425 million private placement to pivot towards cryptocurrency, specifically investing in Ether, and rebrand as ETHZilla Corporation.
2. The company's stock has plummeted over 99.9% since its 2020 IPO, now trading below $3.00, with an accumulated deficit of over $141.5 million and a working capital deficit of approximately $1.6 million.
3. The firm's decline is attributed to lack of revenue, mounting losses, and repeated shareholder dilution to raise capital.
4. Other companies like Mill City Ventures, Nature’s Miracle, and Upexi are also pivoting to crypto, investing in assets like Sui, XRP, and Solana.
5. Standard Chartered predicts companies could eventually hold up to 10% of Ether’s total supply as crypto treasury strategies gain momentum.
Description
The Nasdaq-listed biotechnology firm is raising $425 million for its ETH strategy, joining a parade of penny stocks investing in cryptocurrencies as their business flounders.
Latest News
- AML Bitcoin founder gets 7 years in prison for crypto fraud2025-07-30 06:43:51
- Bank of Korea to launch virtual asset committee to monitor crypto2025-07-30 06:28:22
- Kraken seeks $500M at $15B valuation ahead of rumoured 2026 IPO: Report2025-07-30 05:45:25
- Samourai Wallet co-founders to now plead guilty to US charges2025-07-30 04:08:09
- MARA Holdings posts Q2 revenue beat with 64% year-on-year jump2025-07-30 03:38:49